Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam

Nguyen, Dung; Tran, Tuan; Nghiem, Ngoc My; Le, Phuong; Vo, Quang Minh; Day, Jeremy; Rahman, Motiur; Le, Hung

doi:10.1371/journal.pone.0233446

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 The e cacy of pan-genotypic DDAs might be suboptimal for these local endemic subtypes as clinical trials covered mainly the global epidemic genotypes/subtypes. [14][15][16][17] Moreover, the geographic differences in distribution of HCV genotypes and subtypes could re ect the epidemiological history of the virus, 18 understanding these local endemic subtypes could help to improve public health strategies to prevent further transmission and spreading.…”

Section: Discussionmentioning

confidence: 99%

Geographic Variation of Indigenous Hepatitis C Virus Subtypes 6g and 6w in an Endemic Area of Southern Taiwan

Tung¹,

P²,

Chen³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background and Aims: Hepatitis C virus (HCV) genotype (GT) 6 is the most genetically diverse GT and mainly distributed in Southeast Asia and south China but not Taiwan. Earlier studies showed the major GTs in Taiwan were GT 1b and GT 2 with very rare GT6 except in injection drug user and subtype 6a is the main GT 6 subtype among IDUs. Recently we reported a much higher prevalence (18.3%) of GT 6 in Tainan City, southern Taiwan. This study was designed to clarify the subtypes of GT 6 in this endemic area. Materials and Methods: A total 3022 (1343 men and 1679 women) HCV patients were enrolled. GT 6 subtypes were determined by sequencing of core/E1 and nonstructural protein 5B (NS5B) in 322 of 518 GT 6 patients. Results: The overall GT6 prevalence rate was 17.1% (518/3022) with higher prevalence districts located in northern Tainan. The major GT6 subtypes in Tainan were 6g (81.0%), followed by 6w (10.8%), 6a (7.5%), and 6n (0.7%).Conclusions: The high GT 6 prevalence in Tainan was mainly due to subtype 6g and 6w with characteristic geographic distribution, suggesting subtypes 6g and 6w could be indigenous in Tainan for centuries.

show abstract

Section: Discussionmentioning

confidence: 99%

Geographic Variation of Indigenous Hepatitis C Virus Subtypes 6g and 6w in an Endemic Area of Southern Taiwan

Tung¹,

P²,

Chen³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Even in the era of interferon-free, pan-genotypic direct acting antivirals (DAAs), some rare subtypes might harbor intrinsic resistance to DAAs [ 1 ]. The efficacy of pan-genotypic DDAs might be suboptimal for these local endemic subtypes, as clinical trials covered mainly the global epidemic genotypes/subtypes only [ 1 , 2 , 3 , 4 ]. Moreover, the geographic differences in distribution of HCV genotypes and subtypes could reflect the epidemiological history of the virus [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution

Tung

Lee

Chen

et al. 2021

Viruses

View full text Add to dashboard Cite

Hepatitis C virus (HCV) genotype (GT) 6 is the most genetically diverse GT and mainly distributed in Southeast Asia and south China but not Taiwan. Earlier studies showed the major HCV GTs in Taiwan were GT 1b and 2 with very rare GT 6 except in injection drug users (IDUs), and subtype 6a is the main GT 6 subtype among IDUs. Recently, we reported a much higher prevalence (18.3%) of GT 6 in Tainan City, southern Taiwan. This study was designed to clarify the subtypes of GT 6 in this endemic area. A total of 3022 (1343 men and 1679 women) HCV viremic patients were enrolled. Subtypes of GT 6 were determined by sequencing of core/E1 and nonstructural protein 5B in 322 of 518 GT 6 patients. The overall GT 6 prevalence rate was 17.1% (518/3022), with higher prevalence districts (>25%) located in northern Tainan. A novel 6g-related subtype is the most prevalent subtype (81.0%), followed by 6w (10.8%), 6a (7.5%), and 6n (0.7%). The high GT 6 prevalence in Tainan was mainly due to a novel 6g-related subtype and 6w. These two subtypes could be indigenous in Tainan with characteristic geographic distribution.

show abstract

High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study

Flower

McCabe

Ngoc

et al. 2021

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Genotype 6 is the most genetically diverse lineage of hepatitis C virus (HCV), and predominates in Vietnam. It can be treated with sofosbuvir with daclatasvir (SOF/DCV), the lowest costing treatment combination globally. In regional guidelines, longer treatment durations of SOF/DCV (24 weeks) are recommended for cirrhotic individuals, compared with other pangenotypic regimens (12 weeks), based on sparse data. Early on-treatment virological response may offer means of reducing length and cost of therapy in patients with liver fibrosis. Methods In this prospective trial in Vietnam, genotype 6-infected adults with advanced liver fibrosis or compensated cirrhosis were treated with SOF/DCV. Day 14 viral load was used to guide duration of therapy: participants with viral load <500 IU/ml at day 14 were treated with 12 weeks of SOF/DCV and those ≥500 IU/ml received 24 weeks. Primary endpoint was sustained virological response. Findings Of 41 individuals with advanced fibrosis or compensated cirrhosis who commenced treatment, 51% had genotype 6a, 34% 6e. The remainder had 6h, 6k, 6l or 6o. 100% had viral load <500 IU/ml by day 14, meaning all received 12 weeks of SOF/DCV. 100% achieved SVR12 despite a high frequency of putative NS5A inhibitor resistance-associated substitutions (RAS) at baseline. Interpretation 12 weeks of SOF/DCV achieves excellent cure rates in this population. This data supports the removal of costly genotyping in countries where genotype 3 prevalence in <5%, in keeping with WHO guidelines. NS5A-resistance associated mutations in isolation, do not affect efficacy of SOF/DCV therapy. Wider evaluation of response-guided therapy is warranted.

show abstract

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam

Cited by 5 publications

References 29 publications

Geographic Variation of Indigenous Hepatitis C Virus Subtypes 6g and 6w in an Endemic Area of Southern Taiwan

Geographic Variation of Indigenous Hepatitis C Virus Subtypes 6g and 6w in an Endemic Area of Southern Taiwan

Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution

High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study

Contact Info

Product

Resources

About